Polycyclic aromatic hydrocarbons potentiate high-fat diet effects on intestinal inflammation

Ayman Khalil, Pierre-Henri Villard, Anh Dao Maih, Rémy Burcelin, Serge Champion, Francis Fouchier, Jean-François Savouret, Yves Barra, Eric Sérée

To cite this version:

Polycyclic aromatic hydrocarbons potentiate high-fat diet effects on intestinal inflammation and type 2 diabetes

KHALIL1 Ayman, VILLARD1,2 Pierre-Henri, MAIH1 Anh Dao, BURCELIN2 Rémy, CHAMPION1 Serge, FOUCHEIR1 Francis, SAVOURET3 Jean-Francois, BARRA1 Yves, SEREE1 Eric

1 INRA, UMR1260 Nutriments Lipidiques et Prévention des Maladies Métaboliques, Université de la Méditerranée, 27 boulevard Jean-Moulin, Marseille, F-13385, France;
2 INSERM U858 Institute of Molecular Medicine, IFR31, Rangueil Hospital, Toulouse, France
3 UMR-747-Inserm; Université Paris Descartes, UFR Biomédicale, 45 rue des Saints-Pères 75006 Paris, France

Corresponding authors. Email addresses eric.seree@pharmacie.univ-mrs.fr (E. Seree); pierre-henri.villard@pharmacie.univ-mrs.fr (PH Villard) Tel/Fax: (33) 4 91 83 55 94
Abstract

We demonstrate that intestinal inflammation caused by the environmental contaminant benzo[a]pyrene increases the risk of developing type 2 diabetes. Our in vivo results indicate that a high-fat diet (HFD) induces a pre-diabetic state in mice compared with animals fed normal chow. HFD increased IL-1βmRNA concentration in the jejunum, colon, and liver, and TNFα was increased in the colon and strongly increased in the liver. HFD also increased the expression of other genes related to type 2 diabetes, such as the uncoupling protein UCP2, throughout the bowel and liver, but not in the colon. The treatment of HFD with BaP enhanced the expression of IL-1β in the liver and TNFα throughout the bowel and in the liver. Adding BaP to the diet also caused a significant decrease in the expression of the incretin glucagon-like peptide 1, which plays an important role in insulin secretion. Our results suggest that intestinal inflammation may be involved in the onset of type 2 diabetes and that chronic exposure to environmental polycyclic aromatic hydrocarbons can increase the risk of type 2 diabetes by inducing pro-inflammatory cytokine production.

Key words: Inflammation, high-fat diet, polycyclic aromatic hydrocarbon, benzo(a)pyrene, type 2 diabetes, GLP-1
**Introduction**

Polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]pyrene (BaP) are major environmental contaminants. PAHs are generated primarily from incomplete combustion of organic materials and are found in charcoal-barbecued foods. Mainly through the Ah receptor (AhR) signaling pathway, PAHs regulate the expression of several genes including pro-inflammatory cytokines. Cells exposed to PAHs overexpressed IL-1β, IFNγ and IL-8 [1,2,3]. Similar results were obtained with other AhR ligands, such as dioxins, which trigger the induction of IL-1β and TNFα in hepatic inflammation.

Several studies have shown that cigarette smoking increases the risk of type 2 diabetes (T2D) [4]. Smokers are more resistant than non-smokers to insulin-mediated glucose uptake and more hyperinsulinemic in response to an oral glucose load [5]. In the same way, persons exposed to dioxins or polychlorobiphenyls (PCBs) are at higher risk for metabolic diseases such as T2D [6]. Dioxins and PCBs are also well-known AhR ligands [7], and are present at various levels in food.

Most people with T2D are overweight, have low physical activity, and have relatives with diabetes. Poor dietary habits are definitely considered as a major risk factor responsible for the increased occurrence of diabetes today [8]. Several studies have shown that inflammation is closely correlated with the development of T2D [9], as attested by the high plasma concentration of C-reactive protein CRP and pro-inflammatory cytokines IL-6 and TNFα [10]. Hence both genetic and environmental factors, such as diet, physical inactivity, smoking and oxidative stress are responsible for the initiation and progression of chronic inflammation [11]. The origin of the inflammation is unknown, but a recent original hypothesis suggested that high-fat diet-induced obesity was associated with gut inflammation and with a modification of the gut microflora [12,13].

We hypothesized that BaP could potentiate the development of HFD-induced T2D through the modulation of the expression of genes implicated in inflammatory response and oxidative balance in the bowel. The aim of the present study was therefore to investigate the effects of BaP in the context of high-fat diet-induced diabetes on gut inflammation and its influence on the development of T2D.
Materials and methods

Animal preparation and treatment

Four- to five-week-old male C57B6/6J mice (IFFACREDO, L’Arbresle, France) were maintained on three types of diet: a normal chow diet (NC, energy content: 12% fat, 28% protein, and 60% carbohydrate), a high-fat diet (HFD) (energy content: 72% fat comprising corn oil and lard, 28% protein, and < 1% carbohydrate), as described [14], and a high-fat diet supplemented with benzo[a]pyrene (BaP, 2.5 mg/kg bw) for 5 weeks. Ten mice per cage were kept under an 8 am-to-8 pm dark cycle. Blood was collected at 2 pm in the fed state. For fasting experiments and blood sampling, food was removed at 8 pm, and the mice were kept in a new clean cage for 6 h. During the study, food intake, weight gain and glycemia were measured as previously described [15,16].–

Intraperitoneal glucose tolerance test

An intraperitoneal glucose tolerance test (IPGTT),) was given to 6 h-fasted mice after one month (5 weeks) of diet treatment (intraperitoneal injection of 1 g/kg body weight of glucose). Blood glucose levels were monitored from the tip of the tail vein with a glucose meter (Roche Diagnostic, Rotkreuze, Switzerland) from a 3.5 µl sample of tail blood at -30, 0, 30, 60, and 90 min after glucose injection [17]. Areas under the curve (AUC) ( -30-90) were calculated for each group HFD, HFD+BaP and the NC group.

RNA extraction and real time PCR

At the end of treatment the animals were sacrificed, and the four parts of the bowel and the liver were excised. Total RNA was isolated from the tissues using Trizol reagent (Invitrogen, France), RNA was quantified by NanoDrop (NanoDrop technologies Inc., France). Total RNA (1 µg) was reverse-transcribed using Moloney murine leukemia virus reverse-transcriptase (Invitrogen, Cergy-Pontoise, France) and random primers at 42 °C for 1 h. The expression of target genes was determined using the Lightcycler 480 System (Roche, France). To avoiding pipetting errors we used a Biomek3000 pipetting robot equipped with a 96-channel head (Bekman and Coulter). PCR was performed with 0.5 µM of each primer and with the LightCycler and Mastermix Plus for SYBR™GreenI No ROX, in a total volume of 10 µl. Cycling conditions were as follows: 10 min denaturing at 95 °C, followed by 40 cycles of 30 s denaturing at 95 °C, 30 s primer annealing at 60 °C and 30 s fragment elongation at 72 °C. The melting curve was analyzed with the LightCycler® 480 gene scanning software.
Mouse IL-1β, TNFα, IL-10, TGFβ, GLP-1, UCP2, and UPC3 expressions were normalized to β2-actin expression and data quantified by the method of $2^{-\Delta\Delta Ct}$ [18]. The primers used are listed in Table 1.

**Statistical analysis**

Statistical analysis was performed using the Mann-Whitney test by means of GraphPad Software. Values were considered statistically different when $P < 0.05$. Results are presented as means ± SD.
Results
We analyzed the effect of HFD compared with NC on the inflammatory state linked to type 2 diabetes. We studied, on the same genes, the effect of a supplementation of HFD with BaP (HFD+BaP) compared with the HFD alone. The tissues studied were the segmented bowel (duodenum, jejunum, ileum and colon) and the liver.

Effect of HFD versus NC diet on the intestinal and hepatic expression of some target genes (Fig. 1)
We observed a significant induction by HFD of pro-inflammatory IL-1β gene expression in the jejunum (2.8-fold) and colon (1.8-fold).
We also analyzed the gene expression of another pro-inflammatory cytokine, TNFα. TNFα was only significantly induced in the colon (1.7-fold). In the liver, the gene expression of both cytokines IL-1β and TNFα were strongly induced by the HFD (2.8-fold and 13.9-fold respectively).
To check the anti-inflammatory response, the expression of TGFβ and IL-10 genes was analyzed. The results indicate that in the bowel, TGFβ expression was significantly induced in the jejunum (1.7-fold) and colon (1.5-fold) similarly to what was observed for IL-1β. No significant variation in TGFβ expression was observed in the duodenum or ileum. The expression of IL-10, which plays an important role in the inflammatory homeostasis of the bowel, was also analyzed. This anti-inflammatory cytokine was significantly down-regulated in the ileum (0.25-fold) and colon (0.5-fold). IL-10 gene expression was not detected in the upper bowel (duodenum and jejunum).
In the liver, we did not observe any significant variation in either TGFβ or IL-10 gene expression.
We also analyzed the expression of uncoupling proteins 2 and 3 (UCP-2 and UCP-3) involved in the oxidative status, which play an important role in metabolic syndrome [19]. The results presented indicated that UCP2 expression was significantly increased in the upper bowel, in particular in the duodenum, jejunum and ileum (3.7-, 2.5- and 1.6-fold increase respectively). In contrast, a significant decrease of UCP2 expression was observed in the colon (0.8-fold).
We also analyzed UCP3 gene expression. This gene was induced in the jejunum (2.6-fold) and ileum (1.8-fold).
In the liver, gene expression of UCP2 was significantly induced (1.9-fold). UCP3 was not detected in this tissue.
**Effect of BaP added to HFD versus HFD on the intestinal and hepatic expression of some target genes (Fig 2)**

The presence of BaP in HFD did not affect HFD-induced IL-1β gene expression in the bowel or liver. In contrast, TNFα was significantly induced (around 2-fold) in all tested tissues except for the ileum.

Concerning genes associated with the anti-inflammatory response, the addition of BaP significantly decreased the expression of TGFβ in the ileum and slightly in the rest of the bowel. No significant variation was observed in the liver. In contrast, IL-10 expression was significantly increased in the colon (1.4-fold) and liver (2-fold).

UCP2 expression was significantly decreased in response to addition of BaP only in the upper bowel: duodenum (0.4-fold) and jejunum (0.7-fold). By contrast, this gene was significantly induced in the liver (2.2-fold).

No significant variation was observed in UCP3 expression in the jejunum, ileum, colon or liver.

To evaluate the physiological effects of the diet, we analyzed the glucagon-like peptide 1 incretin (GLP-1), which is known to play an essential role in insulin secretion, and the biochemical data characteristics of type 2 diabetes (food intake, weight, and IPGTT).

The results presented in Figure 1 indicate that compared with a normal diet, GLP-1 was not significantly modulated by HFD in the ileum or colon. Compared with HFD alone, the presence of BaP in HFD significantly decreased GLP-1 gene expression in the ileum (0.4-fold) and colon (0.4-fold). No expression of this gene was found in the liver, jejunum or duodenum.

**Effect of HFD or BaP added to HFD on food intake**

As shown in Figure 3A, no significant variation of food intake was observed during the treatment when the HFD mice were compared with the NC diet mice. The same results were observed when the HFD+BaP mice were compared with HFD mice.

**Effect of HFD or BaP added to HFD on body weight gain**

As shown in Figure 3B, no significant body weight gain was observed during the treatment when the HFD mice were compared with the NC diet mice. The same results were observed when we compared the HFD+BaP group with the HFD group.
Effect of HFD or BaP added to HFD on glucose tolerance

As shown in Figure 3C, HFD mice exhibited significant glucose intolerance when compared with the normal chow diet mice, as evidenced by the significant higher AUC calculated from glucose profiles (Fig.3D). By contrast, no significant glucose intolerance was observed when the HFD+BaP mice were compared with the HFD mice (Fig. 3C and D).

Discussion

T2D is a major public health concern. It is closely linked to obesity, and is associated with an increased risk of cardiovascular events. Although genetic predispositions to T2D have been described, environmental factors play a major role in the etiology of this metabolic disease. The influences of a hypercaloric diet associated with a decrease in physical activity have been widely described as the main factors in decreased insulin sensitivity. However, epidemiological studies have demonstrated that other environmental factors are also involved. It has now been clearly demonstrated that environmental exposure to dioxins and polychlorobiphenyls (PCB) is associated with an increased the risk of T2D and metabolic syndrome [20,21,22,23]. Similar effects have been observed in tobacco smokers [24,25,26]. Dioxins, PCBs and PAHs are well-known AhR ligands [27,28]. Although extensive data demonstrate that these chemicals enhance susceptibility to chemical carcinogenesis by inducing CYP1 expression, much recent work shows that AhR activation leads to an induction of pro-inflammatory cytokines such as IL-1β and TNFα [29,30]. T2D and decreased insulin sensitivity have been associated with an increase in circulating TNFα levels. It is known that the increase in TNFα is a consequence of the inflammation of the visceral adipose tissue.

We investigated the involvement of the bowel in the nutrient-induced inflammatory response, given that this tissue has primary contact with food. We compared the response of the bowel with that of the liver.

As diabetes is known to be associated with some disturbances of inflammatory status, we analyzed the inflammatory gene expression in response to HFD, in both the bowel and the liver. The induction of inflammation following HFD is already well-documented in the liver and our results are consistent with previous published data [12, 34, 35]. In the bowel, amplitude of the inflammatory response was specific to the intestine segment considered. Alltogether, the study of intestinal IL-1β and TNFα expression shows that the response was similar to what was observed in the liver. We note that except in the colon, we found in all
parts of the bowel an association between pro-inflammatory gene expression and UCP induction. As previously reported by others, no TGFβ or IL10-induced anti-inflammatory response was observed in the liver. However, in the jejunum and colon, but not in the duodenum or ileum, TGFβ seems to play an important role after HFD by counteracting the inflammatory process. When BaP was added to HFD, we observed an amplification of the inflammatory response in both the bowel and the liver. Compared with IL-1β, TNFα appears as the main inflammatory cytokine enhanced in response to the presence of BaP in HFD. The HFD-induced anti-inflammatory response, represented by TGFβ expression, was reduced by BaP treatment in all parts of the intestine. Thus in the presence of BaP, the HFD-induced inflammation status was amplified through both an enhancement of pro-inflammatory cytokines and a down-regulation of anti-inflammatory cytokines. This process, induced first in the intestine, may contribute to further deterioration of the metabolism. By contrast, in both the colon and the liver, HDF-induced IL-10 expression was further enhanced by addition of BaP. In this case, the colon and liver displayed similar patterns of anti-inflammatory response. The up-regulation of IL10 we observed in the liver and colon may be the main factor that reduces the inflammatory process in these tissues. These data indicate that the bowel, the first target of food constituents, may play a role in the modulation of the inflammatory status.

We analyzed the expression of uncoupled proteins (UCP2 and UCP3), which are modulators of inflammatory response mediated by redox balance and linked to diabetes emergence. In general, in various tissues already analyzed, expression of the UCP gene family was increased by HFD. UCP2 was induced by the HFD in the main parts of the bowel comprising the duodenum, jejunum and ileum. This response is similar to that observed in the liver as reported in this work and elsewhere [31,32]. By contrast, the colon presents a different pattern of UCP2 expression, with a decrease in its expression. UCP3 was detected in the jejunum, ileum and colon with only a significant induction in the jejunum. These data are original and, to our knowledge, no data were available concerning the expression of UCP2/3 in the different parts of the bowel compared with the liver. Thus as previously reported by others in the liver [31,32,33], HFD modifies UCP2/3 expression, and this response appears to be differently regulated according to the part of intestine tested. When added to HFD, BaP partially counteracted the effect of HFD on UCP2 expression, which was found to be decreased in the upper bowel, including the duodenum and jejunum. However, this response was opposite to that of the liver, where BaP enhanced the HFD-induced UCP2 expression. Thus unexpectedly, the disturbance of metabolism induced by HFD seems to be ‘normalized’
in the bowel by BaP addition, but amplified in the liver. BaP induced no variation in UCP3 expression, showing that the effects of BaP are gene-specific.

We further analyzed the effect of HFD alone or BaP+HFD on GLP-1 expression, since it normalizes blood glucose level by increasing circulating insulin and decreasing glucagon secretion. When BaP was added to HFD, we observed a significant decrease in GLP-1 expression in the bowel, particularly in the terminal parts ileum and colon. AhR ligands, acting as inflammatory compounds and decreasing GLP-1 expression may be involved in the onset of diabetes. Biochemical data (IPGTT) show that HFD treatment reduced insulin sensitivity, but BaP supplementation did not modify this effect.

Overall, our findings show that the bowel may play a role in this process.

**Conclusion**

Our results show that PAHs, by activating AhR, are involved in the potentiation of the inflammatory process induced by HFD. The inflammation occurs in the bowel, one of the first organs exposed to dietary constituents. This inflammation may be involved in the inflammatory stimulation of other organs such as the liver. In the bowel, the colon seems to play a specific role in this effect.

**References**


[29] F. Fane, B. Yan, G. Wood, M. Viluksela, K.K. Rozman, Cytokines (IL-1β and TNFα) in relation to biochemical and immunological effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats, Toxicology. 116 (1997) 9-16.


**Figure legends**

**Fig.1.** Effect of high-fat diet (HFD) *versus* normal chow diet mice (NC) on relative gene expression levels in the bowel (duodenum, jejunum, ileum and colon) and liver of five-week-old male C57B6/6J mice. *: $p < 0.05$, **: $p < 0.01$. ND: not done, UD: undetected.

**Fig.2.** Effect of benzo[a]pyrene added to high-fat diet (HFD+BaP) *versus* high-fat diet mice (NC) on relative gene expression levels in the bowel (duodenum, jejunum, ileum and colon) and liver of five-week-old male C57B6/6J mice. *: $p < 0.05$, **: $p < 0.01$. ND: not done, UD: undetected.

**Fig.3.** Effect of HFD or BaP added to HFD on the biochemical data characteristics of type 2 diabetes of five-week-old male C57B6/6J mice. A: Food intake (g) for 5 weeks of treatment. B: Body weight (g). C: glycemia after 5 weeks of dietary treatment were calculated at 30, 0, 30, 60 and 90 min after glucose injection. D: areas under the curves (AUCs) of glucose tolerance tests calculated from Fig 3, C. Results are mean ± SD. **: $p < 0.01$, ***: $p < 0.001$.

<table>
<thead>
<tr>
<th>Genes</th>
<th>Forward sequence (5'-3')</th>
<th>Reverse sequence (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>β2-actin</td>
<td>5'-AAGGCCAACCCTGAAAAAGAT-3'</td>
<td>5'-TGGTACGACCAGAGGCATAC-3'</td>
</tr>
<tr>
<td>TNFα</td>
<td>5'-GGGACAGTGACCTGGACTGT-3'</td>
<td>5'-TTCGGAAAAGCCCATTTTGAGT-3'</td>
</tr>
<tr>
<td>IL-1β</td>
<td>5'-TCGCTCAGGGTCAACAAGAAA-3'</td>
<td>5'-CATCAGAGGCAAGGAGGAAA-3'</td>
</tr>
<tr>
<td>TGF-β</td>
<td>5'-TGGAGCAACATGTGGAACTG-3'</td>
<td>5'-GTCAGCACGGGTATACACA-3'</td>
</tr>
<tr>
<td>IL-10</td>
<td>5'-CACAAAGCAGCCTTGCAAGA-3'</td>
<td>5'-AGAGCAGGAGTACAGTGT-3'</td>
</tr>
<tr>
<td>Gene</td>
<td>Forward Sequence</td>
<td>Reverse Sequence</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>UCP-2</td>
<td>5'-CTCCCAATGTGCCCCTAAT-3'</td>
<td>5'-GGCTTTCAGGAGGTATCTTTGA-3'</td>
</tr>
<tr>
<td>UCP-3</td>
<td>5'-GCTGGAGTCTCCTGTTTACT-3'</td>
<td>5'-ACAGAAGCCAGCTCCAAAGG-3'</td>
</tr>
<tr>
<td>GLP-1</td>
<td>5'-ACATGCTGAAGGACCTTTAC-3'</td>
<td>5'-GGCTTTCACCAGCCAC-3'</td>
</tr>
</tbody>
</table>
Duodenum

Jejunum

Ileum

Colon

Liver

Fig.1.
Fig. 2.
Fig. 3.

A. Food intake

B. Body weight

C. IPGTT

D. AUCs